Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | Melanoma | Research

Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years

Authors: Wan Hu, Lanlan Fang, Ruyu Ni, Hengchuan Zhang, Guixia Pan

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

The disease burden of non-melanoma skin cancer (NMSC) has become a significant public health threat. We aimed to conduct a comprehensive analysis to mitigate the health hazards of NMSC.

Methods

This study had three objectives. First, we reported the NMSC-related disease burden globally and for different subgroups (sex, socio-demographic index (SDI), etiology, and countries) in 2019. Second, we examined the temporal trend of the disease burden from 1990 to 2019. Finally, we used the Bayesian age-period-cohort (BAPC) model integrated nested Laplacian approximation to predict the disease burden in the coming 25 years. The Norpred age-period-cohort (APC) model and the Autoregressive Integrated Moving Average (ARIMA) model were used for sensitivity analysis.

Results

The disease burden was significantly higher in males than in females in 2019. The results showed significant differences in disease burden in different SDI regions. The better the socio-economic development, the heavier the disease burden of NMSC. The number of new cases and the ASIR of basal cell carcinoma (BCC) were higher than that of squamous cell carcinoma (SCC) in 2019 globally. However, the number of DALYs and the age-standardized DALYs rate were the opposite. There were statistically significant differences among different countries. The age-standardized incidence rate (ASIR) of NMSC increased from 54.08/100,000 (95% uncertainty interval (UI): 46.97, 62.08) in 1990 to 79.10/100,000 (95% UI: 72.29, 86.63) in 2019, with an estimated annual percentage change (EAPC) of 1.78. Other indicators (the number of new cases, the number of deaths, the number of disability-adjusted life years (DALYs), the age-standardized mortality rate (ASMR), and the age-standardized DALYs rate) showed the same trend. Our predictions suggested that the number of new cases, deaths, and DALYs attributable to NMSC would increase by at least 1.5 times from 2020 to 2044.

Conclusions

The disease burden attributable to NMSC will continue to increase or remain stable at high levels. Therefore, relevant policies should be developed to manage NMSC, and measures should be taken to target risk factors and high-risk groups.
Appendix
Available only for authorised users
Literature
1.
Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs. 2013;29(3):160–9.PubMedCrossRef
2.
3.
4.
Amaral T, Garbe C. Non-melanoma skin cancer: new and future synthetic drug treatments. Expert Opin Pharmacother. 2017;18(7):689–99.PubMedCrossRef
5.
Cheraghi N, Cognetta A, Goldberg D. Radiation therapy in dermatology: non-melanoma skin Cancer. J Drugs Dermatol. 2017;16(5):464–9.PubMed
6.
Chua B, Jackson JE, Lin C, Veness MJ. Radiotherapy for early non-melanoma skin cancer. Oral Oncol. 2019;98:96–101.PubMedCrossRef
7.
Garrido PM, Borges-Costa J. Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: review of the literature. Rev Port Cardiol (Engl Ed). 2020;39(3):163–70.CrossRef
8.
Garbutcheon-Singh KB, Veness MJ. The role of radiotherapy in the management of non-melanoma skin cancer. Australas J Dermatol. 2019;60(4):265–72.PubMedCrossRef
9.
Aggarwal P, Knabel P, Fleischer AB Jr. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol. 2021;85(2):388–95.PubMedCrossRef
10.
Kornek T, Augustin M. Skin cancer prevention. J Dtsch Dermatol Ges. 2013;11(4):283–96 quiz 297-288.PubMed
11.
Liang J, Li X, Kang C, Wang Y, Kulikoff XR, Coates MM, et al. Maternal mortality ratios in 2852 Chinese counties, 1996-2015, and achievement of millennium development goal 5 in China: a subnational analysis of the global burden of disease study 2016. Lancet. 2019;393(10168):241–52.PubMedPubMedCentralCrossRef
12.
13.
Pondicherry A, Martin R, Meredith I, Rolfe J, Emanuel P, Elwood M. The burden of non-melanoma skin cancers in Auckland, New Zealand. Australas J Dermatol. 2018;59(3):210–3.PubMedCrossRef
14.
Cakir B, Adamson P, Cingi C. Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast Surg Clin North Am. 2012;20(4):419–22.PubMedCrossRef
15.
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017. A systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1923–94.PubMedPubMedCentralCrossRef
16.
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver Cancer and underlying etiologies from 1990 to 2015 at the global, regional, and National Level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91.PubMedPubMedCentralCrossRef
17.
Kansara S, Bell D, Weber R. Surgical management of non melanoma skin cancer of the head and neck. Oral Oncol. 2020;100:104485.PubMedCrossRef
18.
Conforti C, Corneli P, Harwood C, Zalaudek I. Evolving role of systemic therapies in non-melanoma skin Cancer. Clin Oncol (R Coll Radiol). 2019;31(11):759–68.CrossRef
19.
Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010. Lancet. 2012;380(9859):2129–43.PubMedCrossRef
20.
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.PubMedPubMedCentralCrossRef
21.
Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223–49.
22.
Shan Y, Xu Y, Ye L, Lin X, Chen Y, Miao Q, et al. Socioeconomic disparity in global vision loss burden due to diabetic retinopathy: an analysis on time trends from 1990 to 2017. Endocrine. 2021;73(2):316–24.PubMedCrossRef
23.
Molassiotis A, Kwok SWH, Leung AYM, Tyrovolas S. Associations between sociodemographic factors, health spending, disease burden, and life expectancy of older adults (70 + years old) in 22 countries in the Western Pacific region, 1995-2019: estimates from the global burden of disease (GBD) study 2019. Geroscience. 2022;44(2):925–51.PubMedPubMedCentralCrossRef
24.
Du Z, Chen W, Xia Q, Shi O, Chen Q. Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study. Biomark Res. 2020;8:16.PubMedPubMedCentralCrossRef
25.
Møller B, Fekjaer H, Hakulinen T, Sigvaldason H, Storm HH, Talbäck M, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003;22(17):2751–66.PubMedCrossRef
26.
Vollset SE, Goren E, Yuan CW, Cao J, Smith AE, Hsiao T, et al. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the global burden of disease study. Lancet. 2020;396(10258):1285–306.PubMedPubMedCentralCrossRef
27.
Sampogna F, Paradisi A, Iemboli ML, Ricci F, Sonego G, Abeni D. Comparison of quality of life between melanoma and non-melanoma skin cancer patients. Eur J Dermatol. 2019;29(2):185–91.PubMed
28.
Wu X, Elkin EE, Marghoob AA. Burden of basal cell carcinoma in USA. Future Oncol. 2015;11(22):2967–74.PubMedCrossRef
29.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.PubMedCrossRef
30.
Stonesifer CJ, Djavid AR, Grimes JM, Khaleel AE, Soliman YS, Maisel-Campbell A, et al. Immune checkpoint inhibition in non-melanoma skin Cancer: a review of current evidence. Front Oncol. 2021;11:734354.PubMedPubMedCentralCrossRef
31.
Arenas M, Arguís M, Díez-Presa L, Henríquez I, Murcia-Mejía M, Gascón M, et al. Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment. Brachytherapy. 2015;14(6):859–65.PubMedCrossRef
32.
Perera E, Gnaneswaran N, Staines C, Win AK, Sinclair R. Incidence and prevalence of non-melanoma skin cancer in Australia: a systematic review. Australas J Dermatol. 2015;56(4):258–67.PubMedCrossRef
33.
Chu S, Mehrmal S, Uppal P, Giesey RL, Delost ME, Delost GR. Burden of skin disease and associated socioeconomic status in Europe: an ecologic study from the global burden of disease study 2017. JAAD Int. 2020;1(2):95–103.PubMedPubMedCentralCrossRef
34.
Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Non-melanoma skin cancer in Australia. Med J Aust. 2012;197(10):565–8.PubMedCrossRef
35.
36.
Wu S, Han J, Li WQ, Li T, Qureshi AA. Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. Am J Epidemiol. 2013;178(6):890–7.PubMedPubMedCentralCrossRef
37.
Garcovich S, Colloca G, Sollena P, Andrea B, Balducci L, Cho WC, et al. Skin Cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging Dis. 2017;8(5):643–61.PubMedPubMedCentralCrossRef
38.
Larese Filon F, Buric M, Fluehler C. UV exposure, preventive habits, risk perception, and occupation in NMSC patients: a case-control study in Trieste (NE Italy). Photodermatol Photoimmunol Photomed. 2019;35(1):24–30.PubMedCrossRef
39.
Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–40.PubMed
40.
Liu-Smith F, Jia J, Zheng Y. UV-induced molecular signaling differences in melanoma and non-melanoma skin Cancer. Adv Exp Med Biol. 2017;996:27–40.PubMedCrossRef
41.
Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin Cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther (Heidelb). 2017;7(Suppl 1):5–19.CrossRef
42.
Ren J, Ceylan-Isik AF. Diabetic cardiomyopathy: do women differ from men? Endocrine. 2004;25(2):73–83.PubMedCrossRef
43.
44.
Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19(6):984–9.PubMedCrossRef
45.
Molife R, Lorigan P, MacNeil S. Gender and survival in malignant tumours. Cancer Treat Rev. 2001;27(4):201–9.PubMedCrossRef
46.
Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63(1–3):8–18.PubMedCrossRef
47.
Foote JA, Harris RB, Giuliano AR, Roe DJ, Moon TE, Cartmel B, et al. Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults. Int J Cancer. 2001;95(1):7–11.PubMedPubMedCentralCrossRef
48.
Graells J. The risk and risk factors of a second non-melanoma skin cancer: a study in a Mediterranean population. J Eur Acad Dermatol Venereol. 2004;18(2):142–7.PubMedCrossRef
49.
Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41–7.PubMedCrossRef
50.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.PubMedCrossRef
51.
Gawkrodger DJ. Occupational skin cancers. Occup Med (Lond). 2004;54(7):458–63.CrossRef
52.
Lear JT, Tan BB, Smith AG, Jones PW, Heagerty AH, Strange RC, et al. A comparison of risk factors for malignant melanoma, squamous cell carcinoma and basal cell carcinoma in the UK. Int J Clin Pract. 1998;52(3):145–9.PubMed
53.
Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol. 1999;135(7):781–6.PubMedCrossRef
54.
de Kok IM, van Lenthe FJ, Avendano M, Louwman M, Coebergh JW, Mackenbach JP. Childhood social class and cancer incidence: results of the globe study. Soc Sci Med. 2008;66(5):1131–9.PubMedCrossRef
55.
Steding-Jessen M, Birch-Johansen F, Jensen A, Schüz J, Kjær SK, Dalton SO. Socioeconomic status and non-melanoma skin cancer: a nationwide cohort study of incidence and survival in Denmark. Cancer Epidemiol. 2010;34(6):689–95.PubMedCrossRef
56.
Griffin LL, Ali FR, Lear JT. Non-melanoma skin cancer. Clin Med (Lond). 2016;16(1):62–5.CrossRef
57.
Reichrath J, Reichrath S. The relevance of the vitamin D endocrine system (VDES) for tumorigenesis, prevention, and treatment of non-melanoma skin cancer (NMSC): present concepts and future perspectives. Dermatoendocrinol. 2013;5(1):38–50.PubMedPubMedCentralCrossRef
58.
Durmishi A, Fida M, Hoxha S, Naqo X, Bardhi B, Xhelili M, et al. Are military personnel at a more risk for skin cancers? Dermatol Ther. 2020;33(6):e14340.PubMedCrossRef
59.
Rivas M, Rojas E, Calaf GM, Barberán M, Liberman C, De Paula CM. Association between non-melanoma and melanoma skin cancer rates, vitamin D and latitude. Oncol Lett. 2017;13(5):3787–92.PubMedPubMedCentralCrossRef
60.
Metadata
Title
Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years
Authors
Wan Hu
Lanlan Fang
Ruyu Ni
Hengchuan Zhang
Guixia Pan
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-09940-3

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue

Research

Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal

Research

Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?

Research

Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study

Research

Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study

Research

ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer

Research

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits